ProQR Therapeutics NV (OQ:PRQR)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Apr 23, 2024 07:00 am ET

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of...

Apr 22, 2024 04:31 pm ET

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including...

Apr 19, 2024 07:00 am ET

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA...

Mar 13, 2024 07:00 am ET

ProQR Announces Year End 2023 Operating and Financial Results

Feb 15, 2024 07:00 am ET

ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against an opposition filed in Japan against a patent directed to its...

Jan 19, 2024 07:00 am ET

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key updates from its oral presentation at...

Jan 05, 2024 07:00 am ET

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced a collaboration with the Rett Syndrome...

Dec 08, 2023 07:30 am ET

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has completed a transaction divesting late stage ophthalmic assets, sepofarsen and ultevursen, to...

Nov 07, 2023 07:00 am ET

ProQR Announces Third Quarter 2023 Operating and Financial Results

ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today reported its financial and operating results for the...

Nov 06, 2023 07:00 am ET

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has further strengthened its leading intellectual property (IP) estate with the issuance of a new patent...

Sep 28, 2023 08:00 am ET

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Daniel A. de Boer, Founder and CEO,...

Sep 27, 2023 07:00 am ET

ProQR Therapeutics Provides Update on Ophthalmic Assets

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previously announced agreement to divest the Company’s late-stage ophthalmic assets to...

Sep 07, 2023 08:00 am ET

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company management will participate in...

Aug 03, 2023 07:00 am ET

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 01, 2023 07:00 am ET

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, and Laboratoires Théa, the leading independent eye care group in Europe (“Théa”), today announced an agreement in which...

Jul 06, 2023 07:00 am ET

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced a presentation at the RNA Editing Summit,...

May 16, 2023 07:00 am ET

ProQR Announces First Quarter 2023 Operating and Financial Results

May 09, 2023 08:00 am ET

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Apr 20, 2023 08:00 am ET

ProQR Announces Upcoming Investor Conferences in April and May

ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company management will participate in...

Apr 18, 2023 08:00 am ET

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Mar 29, 2023 08:00 am ET

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Mar 14, 2023 08:00 am ET

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against two oppositions that were filed against a key patent for its...

Mar 07, 2023 08:00 am ET

ProQR to Present at Upcoming Scientific and Industry Conferences

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced several presentations highlighting the Company’s proprietary Axiomer® RNA editing technology platform at...

Feb 28, 2023 08:00 am ET

ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual R&D event on Wednesday, March 29, 2023 from 10:00 am until 12:30 pm...

Dec 22, 2022 07:51 am ET

Thinking about buying stock in Thermogenesis Holdings, ProQR Therapeutics, Grom Social, ORIC Pharmaceuticals, or Acasti Pharma?

NEW YORK, Dec. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for THMO, PRQR, GROM, ORIC, and ACST.

Dec 22, 2022 06:15 am ET

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA...

Dec 22, 2022 06:00 am ET

Lilly and ProQR to Expand RNA Editing Collaboration

Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and collaboration agreement focused on the discovery, development and commercialization of new genetic medicines. The...

Dec 22, 2022 05:00 am ET

Lilly and ProQR to Expand RNA Editing Collaboration

New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR's Axiomer technology

Dec 15, 2022 07:39 am ET

Thinking about buying stock in Crown Electrokinetics, ThredUp, Icosavax, Engine Gaming and Media, or ProQR Therapeutics?

NEW YORK, Dec. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRKN, TDUP, ICVX, GAME, and PRQR.

Nov 14, 2022 04:30 pm ET

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES...

Nov 09, 2022 07:00 am ET

ProQR Announces Third Quarter 2022 Operating and Financial Results

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today reported its financial and operating results for the third quarter ended September 30, 2022,...

Nov 03, 2022 07:00 am ET

ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., November 3, 2022 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced that Company management...

Aug 11, 2022 07:00 am ET

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today provided an update on its ophthalmology programs following feedback from the European...

Aug 04, 2022 07:00 am ET

ProQR Announces Second Quarter 2022 Operating and Financial Results

Jun 28, 2022 07:00 am ET

ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced that Company management will participate in the Life Sci 2nd Annual Genetic...

Jun 01, 2022 07:00 am ET

ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced that its 2022 Annual General Meeting of Shareholders will take place on Thursday,...

May 09, 2022 07:00 am ET

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

May 05, 2022 04:30 pm ET

ProQR Announces First Quarter 2022 Operating and Financial Results

Apr 26, 2022 04:10 pm ET

ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced several presentations at the 7th Annual Retinal Cell and Gene Therapy Innovation...

Apr 19, 2022 04:30 pm ET

ProQR to Participate in the Kempen Life Sciences Conference

Apr 13, 2022 07:00 am ET

ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen program, following a comprehensive post-hoc analysis of...

Apr 04, 2022 07:00 am ET

ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a presentation at the 3rd RNA Editing Summit held April 5-7...

Mar 23, 2022 04:30 pm ET

ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will participate in the Cantor...

Mar 07, 2022 07:00 am ET

ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that John Maraganore, PhD, biopharma industry leader and...

Feb 24, 2022 07:00 am ET

ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its financial and operating results for the fourth quarter...

Feb 11, 2022 09:50 am ET

Thinking about buying stock in Senseonics, ProQR Therapeutics, Surgalign, Astra Space, or Under Armour?

NEW YORK, Feb. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SENS, PRQR, SRGA, ASTR, and UAA.

Feb 11, 2022 07:00 am ET

ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced its pivotal Phase 2/3 Illuminate trial of sepofarsen for...

Feb 07, 2022 04:30 pm ET

ProQR to Present at Upcoming SVB Leerink Conference

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will present at the upcoming...

Jan 04, 2022 07:00 am ET

ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that the last patient completed their last visit (Month 12)...

Dec 30, 2021 07:00 am ET

ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that it has amended its convertible debt financing agreement...

Dec 16, 2021 07:00 am ET

ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed in Phase 2/3 Sirius and Celeste clinical trials of...

Nov 18, 2021 04:01 pm ET

ProQR Announces Highlights from Analyst Event

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event. Management provided an in-depth...

Nov 11, 2021 07:00 am ET

ProQR to Webcast Virtual Analyst Event on November 18

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a virtual Analyst Event on November 18, 2021, from 12-2pm ET...

Nov 08, 2021 04:30 pm ET

ProQR Announces Upcoming Investor Conferences in November and December

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will participate in the following...

Nov 04, 2021 07:00 am ET

ProQR Announces Third Quarter 2021 Operating and Financial Results

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its financial and operating results for the third quarter...

Oct 04, 2021 08:00 am ET

ProQR Appoints Theresa Heggie as Chief Commercial Officer

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the appointment of Theresa Heggie as Chief Commercial Officer...

Sep 08, 2021 04:15 pm ET

ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that ProQR management will host an investor conference call and...

Sep 08, 2021 04:01 pm ET

ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), today announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of potential new medicines for genetic...

Sep 06, 2021 04:15 pm ET

ProQR Announces Virtual Presentation at EURETINA 2021

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a virtual oral presentation of data from the Company’s Phase 1/2 Stellar...

Sep 03, 2021 08:00 am ET

ProQR Announces Upcoming Investor Conferences

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will participate in the following...

Aug 11, 2021 04:30 pm ET

ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will present at the upcoming HC...

Aug 05, 2021 07:00 am ET

ProQR Announces Second Quarter 2021 Operating and Financial Results

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its financial and operating results for the second quarter...

Jun 10, 2021 07:00 am ET

ProQR to Present at Upcoming JMP Securities Life Sciences Conference

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will present during a fireside chat...

May 06, 2021 07:00 am ET

ProQR Announces First Quarter 2021 Operating and Financial Results

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its financial and operating results for the first quarter...

May 04, 2021 07:00 am ET

ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target

RTW Investments, LP (“RTW”), a global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors, and ProQR Therapeutics N.V. (Nasdaq:...

Apr 23, 2021 07:00 am ET

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual oral presentation of data from the Company’s Phase 1/2...

Apr 22, 2021 07:00 am ET

ProQR Announces Participation in Upcoming Kempen Life Sciences Conference

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will host 1x1 meetings...

Apr 20, 2021 07:00 am ET

ProQR Announces Annual Meeting of Shareholders

Apr 13, 2021 04:15 pm ET

ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the publication in the scientific journal Nature Medicine titled...

Apr 05, 2021 04:15 pm ET

ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the closing of its previously announced underwritten public...

Apr 02, 2021 04:15 pm ET

ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation at the Annual Meeting of the American...

Mar 30, 2021 10:25 pm ET

ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares

ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the pricing of its previously announced underwritten public...

Mar 30, 2021 04:05 pm ET

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that it intends to offer and sell its ordinary shares in an...

Mar 24, 2021 07:00 am ET

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials

Mar 17, 2021 07:00 am ET

ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome

Mar 02, 2021 04:30 pm ET

ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference

Feb 25, 2021 07:00 am ET

ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today reported its financial and operating results for the...

Feb 16, 2021 04:30 pm ET

ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome

Jan 07, 2021 07:00 am ET

ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10

Dec 18, 2020 07:00 am ET

ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference

Nov 18, 2020 07:00 am ET

ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference

Nov 16, 2020 07:00 am ET

ProQR Announces Third Quarter 2020 Operating and Financial Results

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today reported its financial and operating results for the...

Nov 02, 2020 07:00 am ET

ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO)

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual poster presentations at the Annual Meeting of the American...

Oct 05, 2020 07:00 am ET

ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer

Sep 24, 2020 04:10 pm ET

ProQR Announces Virtual Presentations at Scientific Conferences

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual presentations at the Ophthalmology Futures Retina Forum,...

Sep 03, 2020 07:00 am ET

ProQR to Participate in Upcoming Investor Conferences

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for inherited retinal diseases (IRDs), today announced that Company management will participate in...

Aug 06, 2020 04:30 pm ET

ProQR Announces Second Quarter 2020 Operating and Financial Results

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today reported its financial and operating results for the...

Jul 21, 2020 07:00 am ET

ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the Company’s Scientific Advisory Board (SAB)...

Jul 14, 2020 04:30 pm ET

ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that it has entered into a $30 million convertible debt...

Jul 13, 2020 04:30 pm ET

ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that the Company will host an Expert Perspectives call on July 20,...

Jun 12, 2020 07:00 am ET

ProQR Announces Expert Perspectives Conference Call Series

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that the Company will launch a series of Expert Perspectives calls...

Jun 08, 2020 07:00 am ET

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation of data from the Company’s Phase 1/2 trial of...

May 25, 2020 07:00 am ET

ProQR Announces Annual Meeting of Shareholders

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that the Annual General Meeting of Shareholders...

May 07, 2020 07:00 am ET

ProQR Announces First Quarter 2020 Operating and Financial Results

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today reported its financial results for the first quarter ended...

Mar 31, 2020 06:00 am ET

ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update

March 31, 2020 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announces positive findings from a planned...

Mar 25, 2020 04:15 pm ET

ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that Company management will present and discuss findings from a...

Feb 26, 2020 07:00 am ET

ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today reported its financial results for the fourth quarter and...

Feb 24, 2020 07:00 am ET

ProQR to Present at Cowen and Company 40th Annual Health Care Conference

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that Company management will present at the...

Feb 06, 2020 07:00 am ET

ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, announced today its participation in the Foundation Fighting Blindness My Retina...

Jan 30, 2020 07:00 am ET

ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Rare Pediatric Disease (RPD) designation from the...

Dec 11, 2019 07:00 am ET

ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the first patient dosed in the Phase 1/2 Aurora clinical trial of...

Nov 21, 2019 07:00 am ET

ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Nov 18, 2019 07:23 am ET

ProQR to Present at Upcoming Scientific Conferences

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that Company management will present at two...

Nov 13, 2019 07:00 am ET

ProQR to Present at Upcoming Investor Conferences

Nov 06, 2019 07:00 am ET

ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced results for the third quarter of 2019. “During the...

Oct 18, 2019 08:20 am ET

ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the closing of its previously announced underwritten public...

Oct 15, 2019 11:17 pm ET

ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares

ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the pricing of its previously announced...

Oct 15, 2019 04:13 pm ET

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it intends to offer and sell $50,000,000 of...

Oct 15, 2019 04:08 pm ET

ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

Oct 10, 2019 06:00 am ET

ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced positive top-line results from the PQ-110-001 study, a Phase 1/2...

Oct 07, 2019 07:00 am ET

ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that management will present and discuss top-line results from the...

Sep 30, 2019 07:00 am ET

ProQR to Present at Two Investor Conferences in October

Sep 09, 2019 07:00 am ET

ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Aug 12, 2019 07:00 am ET

ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)

Aug 07, 2019 07:00 am ET

ProQR Announces Financial Results for the Second Quarter of 2019

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results for the second quarter...

Jul 29, 2019 07:00 am ET

European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, announced today that its sepofarsen (QR-110) drug candidate, which...

Jul 02, 2019 07:00 am ET

ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July

Jun 03, 2019 07:00 am ET

ProQR to Present at the JMP Securities Life Sciences Conference

May 15, 2019 07:00 am ET

ProQR to Present at the RBC Capital Markets Healthcare Conference

May 08, 2019 07:00 am ET

ProQR Announces Financial Results for the First Quarter of 2019

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results for the first quarter ended...

Apr 22, 2019 07:00 am ET

ProQR to Present at Three Scientific Conferences in April

Apr 18, 2019 08:35 am ET

New Research: Key Drivers of Growth for Quintana Energy Services, ProQR Therapeutics N.V, Tetraphase Pharmaceuticals, Biomerica, Heat Biologics, and Bellerophon Therapeutics — Factors of Influence, Ma

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Quintana Energy Services Inc. (NYSE:QES), ProQR Therapeutics N.V....

Apr 18, 2019 07:00 am ET

ProQR Announces Annual Meeting of Shareholders

Apr 18, 2019 07:00 am ET

ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, has nominated Bart Filius, Chief Operating Officer (COO) and Chief...

Apr 15, 2019 07:00 am ET

ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

Apr 01, 2019 07:00 am ET

ProQR to Present at the H.C. Wainwright Global Life Sciences Conference

Mar 26, 2019 04:01 pm ET

ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership

Mar 11, 2019 08:00 am ET

ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

Mar 05, 2019 07:00 am ET

ProQR to Present at Cowen Health Care Conference

Feb 27, 2019 07:00 am ET

ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results for the fourth quarter and...

Jan 29, 2019 08:30 am ET

ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines, today announced its “ProQR Vision 2023” strategy, which is focused on the development and commercialization of RNA...

Jan 07, 2019 07:00 am ET

ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10

Jan 03, 2019 07:00 am ET

ProQR to Host R&D Day in New York on January 29

ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January 29 at 8:00 am ET at the Lotte New York Palace Hotel in New York, NY. The R&D day will feature presentations by internal ProQR and...

Jan 02, 2019 07:00 am ET

ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

Dec 24, 2018 07:00 am ET

ProQR Therapeutics Added to NASDAQ Biotechnology Index

Dec 17, 2018 11:52 am ET

ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10

Dec 13, 2018 07:00 am ET

ProQR Announces Strategic Changes to the Management Team and Key New Hires

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced changes to its management team and...

Dec 10, 2018 07:00 am ET

ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10

Dec 04, 2018 07:00 am ET

ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients

Nov 20, 2018 07:00 am ET

ProQR to Present at the Evercore ISI HealthConX Conference

Nov 16, 2018 08:55 am ET

Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences — Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ProQR Therapeutics N.V. (NASDAQ:PRQR), Biomerica, Inc. (NASDAQ:BMRA),...

Nov 07, 2018 07:00 am ET

ProQR Announces Financial Results for the Third Quarter of 2018

Oct 31, 2018 07:00 am ET

ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference

Oct 29, 2018 07:33 am ET

ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals

ProQR Therapeutics N.V. (Nasdaq:PRQR) a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the signing of an agreement with Ionis...

Oct 02, 2018 07:00 am ET

ProQR to Present at the Chardan Genetic Medicines Conference

Sep 24, 2018 07:00 am ET

ProQR Announces Presentations at the OTS Annual Meeting

Sep 11, 2018 04:01 pm ET

ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the closing of its previously...

Sep 07, 2018 04:21 am ET

ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares

ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the pricing of its previously...

Sep 05, 2018 04:01 pm ET

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Sep 05, 2018 04:00 am ET

ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial

Aug 15, 2018 07:00 am ET

ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th

Aug 08, 2018 07:00 am ET

ProQR Announces Financial Results for the Second Quarter of 2018

Aug 01, 2018 07:00 am ET

ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids

Jul 12, 2018 07:00 am ET

ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July

Jun 28, 2018 07:00 am ET

ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa

Jun 14, 2018 07:00 am ET

ProQR to Present at the JMP Life Sciences Conference

Jun 12, 2018 07:00 am ET

ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa

Jun 04, 2018 07:00 am ET

ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference

May 23, 2018 07:00 am ET

ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board

May 09, 2018 07:00 am ET

ProQR Announces Results for the First Quarter of 2018

Apr 30, 2018 07:00 am ET

ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB

LEIDEN, the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the...

Apr 23, 2018 07:00 am ET

ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO

Key Updates

Apr 11, 2018 07:00 am ET

ProQR Announces Annual Meeting of Shareholders

LEIDEN, the Netherlands, April 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including Leber's congenital amaurosis...

Apr 10, 2018 07:00 am ET

ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology

Key Updates

Apr 03, 2018 07:00 am ET

ProQR to Present at Two Upcoming Conferences

LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including Leber's congenital amaurosis...

Mar 05, 2018 07:00 am ET

ProQR to Present at Upcoming Investor Conference

LEIDEN, the Netherlands, March 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's...

Feb 28, 2018 07:00 am ET

ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update

Key updates

Feb 27, 2018 07:00 am ET

ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer

LEIDEN, the Netherlands, Feb. 27, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's...

Feb 12, 2018 07:00 am ET

Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A

COLUMBIA, Md. and LEIDEN, the Netherlands, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Foundation Fighting Blindness and ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that they have entered into a partnership to develop QR-421a for Usher syndrome 2A caused by...

Feb 06, 2018 07:00 am ET

ProQR to Present at Upcoming Scientific Meeting and Investor Conference

LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's...

Jan 08, 2018 07:00 am ET

ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology

LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG). Under the agreement the two companies will...

Dec 27, 2017 07:00 am ET

ProQR Announces Extraordinary General Meeting of Shareholders

LEIDEN, the Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), today announced that an Extraordinary General Meeting of Shareholders will be held on Monday, February 19, 2018, at 16:00 CET, at the offices of the Company...

Nov 29, 2017 07:00 am ET

ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

Key Updates

Nov 21, 2017 07:00 am ET

ProQR to Present at the Annual Piper Jaffray Healthcare Conference

LEIDEN, the Netherlands, Nov. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital...

Nov 20, 2017 07:00 am ET

ProQR Announces Results for the Third Quarter of 2017

Key updates

Nov 14, 2017 07:44 am ET

ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the...

Nov 13, 2017 04:01 pm ET

ProQR Announces Proposed Public Offering of Ordinary Shares

LEIDEN, the Netherlands, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it...

Nov 13, 2017 07:00 am ET

ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness

Key Updates

Nov 09, 2017 07:00 am ET

ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board

Key Updates...

Nov 09, 2017 07:00 am ET

ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board

Key Updates

Oct 24, 2017 07:00 am ET

ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference

LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10 and dystrophic epidermolysis bullosa, today announced details about upcoming presentations and an investor & analyst event at the North American Cystic Fibrosis Conference being held November 2 – 4, 2017 in Indianapolis, Indiana. ...

Sep 25, 2017 04:00 pm ET

ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis

Key updates...

May 01, 2017 07:00 am ET

ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

Key updates...

Mar 01, 2017 07:00 am ET

ProQR to Present at Two Upcoming Investor Conferences in March

LEIDEN, the Netherlands, March 01, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis (CF), Leber's congenital amaurosis Type 10 (LCA 10) and dystrophic epidermolysis bullosa (DEB), today announced that Daniel de Boer, Chief Executive Officer, and Smital Shah, Chief Financial Officer, will present during two upcoming investor conferences this month....

Feb 27, 2017 07:00 am ET

On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day

LEIDEN, the Netherlands, Feb. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis (CF), Leber's congenital amaurosis Type 10 (LCA 10) and dystrophic epidermolysis bullosa (DEB), today announced its support of Rare Disease Day, joining rare disease patients and families, patient organizations and health care providers to raise awareness of rare diseases....

Oct 27, 2016 07:00 am ET

ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients

LEIDEN, the Netherlands, Oct. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that clinical study PQ-010-002, a proof-of-concept study of nasal potential difference (NPD), demonstrated that QR-010 restored CFTR function in a cohort of homozygous ∆F508 cystic fibrosis (CF) patients. The study met its primary endpoint in this cohort as measured by a change in total chloride response following 4 weeks of treatment with QR-010. In the compound heterozygous ∆F508 cohort, no meaningful difference was found. QR-010 was observed to be safe and well-tolerated in b...

Sep 27, 2016 07:00 am ET

ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC

LEIDEN, the Netherlands, Sept. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis Type 10 (LCA10), today announced details about an oral and poster presentation and an Investor & Analyst event on Thursday October 27, 2016 during the North American CF Conference (NACFC) that is being held at Orange County Convention Center on October 27 – 29, 2016 in Orlando, Florida....

Sep 06, 2016 07:00 am ET

ProQR to Present at Scientific and Investor Conferences in September

LEIDEN, the Netherlands, Sept. 06, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis Type 10 (LCA10), today announced that the company will present at a scientific conference and two investor conferences during the month of September....

Aug 17, 2016 07:00 am ET

ProQR Announces Results for the Second Quarter of 2016

LEIDEN, the Netherlands, Aug. 17, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis Type 10 (LCA10), today announced results for the second quarter of 2016....

Jul 19, 2016 07:00 am ET

ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis

LEIDEN, the Netherlands, July 19, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis Type 10 (LCA10), today announced that it received Fast Track designation from the Food and Drug Administration (FDA) for its molecule QR-010 that is in clinical development for the treatment of patients with CF due to the ∆F508 mutation....

Jun 21, 2016 09:00 am ET

ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC

LEIDEN, the Netherlands, June 21, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis Type 10 (LCA10), today announced that topline data from study PQ-010-002, a proof-of-concept study to evaluate the effect of QR-010 on nasal potential difference (NPD) will be released at the time of the North American Cystic Fibrosis Conference (NACFC) held on October 27 - 29, 2016 in Orlando, Flori...

Jun 01, 2016 07:00 am ET

ProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference

LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that the company will present pre-clinical data for QR-010 at the 39th European Cystic Fibrosis Conference (ECFS) held on June 8 – 11, 2016 in Basel, Switzerland and that Smital Shah, Chief Financial Officer, will present during the JMP Securities Life Science Conference held on June 21 - 22, 2016 in New York, NY....

Jun 01, 2016 07:00 am ET

ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation

LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the company’s investigational drug QR-110 has received orphan drug designation (ODD) from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of Leber’s congenital amaurosis Type 10 (LCA10), the most common cause of genetic blindness in childhood....

May 18, 2016 07:00 am ET

ProQR Announces Results for the First Quarter of 2016

LEIDEN, the Netherlands, May 18, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis Type 10 (LCA10), today announced results for the first quarter of 2016....

Ad blocking detected

ProQR Therapeutics NV (OQ:PRQR)

Business Focus: Bio Therapeutic Drugs